Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration
Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration
Decibel Cannabis Company Inc. (TSXV:DB) (OTCQB:DBCCF) has completed the second and final closing of its previously announced non-brokered private placement of its common shares at $0.06 per common share.
Decibel大麻股公司（tsxv:db）（otcqb:dbccf）已經完成其之前宣佈的無中介定向增發的第二輪和最終輪，發行價格爲每股0.06美元。
What Happened
發生了什麼
The company said on Monday that, at the second closing of the offering, it issued 19,647,776 common shares for gross proceeds of roughly $1,178,867.
該公司在週一表示，在此次發行的第二次閉合中，發行了19,647,776股普通股，籌集的毛利率大約爲1,178,867美元。
The second closing was in addition to the previously announced first closing in November when Decibel issued 33,503,864 common shares for gross proceeds of approximately $2,010,232.
第二次閉合是之前在11月宣佈的第一次閉合的補充，當時Decibel發行了33,503,864股普通股，籌集的毛利率約爲2,010,232美元。
Read Also: Decibel's $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio
另請閱讀：Decibel的1000萬策略：它如何增強你的加拿大大麻股投資組合
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Why It Matters
這爲以下原因非常重要
Decibel said the proceeds of the offering will be used to work on and help integrate the integration of AgMedica BioScience Inc. which he company previously acquired. The acquisition was arranged through an agreement with Callisto Capital on Oct. 28 and was made in exchange for a $6.3 million unsecured convertible debenture.
Decibel表示，本次發行的收益將用於開發並幫助整合公司之前收購的AgMedica BioScience Inc.。該收購是通過與Callisto Capital於10月28日達成的協議安排的，作爲交換，發放了一份630萬無擔保可轉換債券。
Decibel projects that AgMedica could contribute $30 million of net revenue and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro forma basis.
Decibel預計AgMedica在2025年將貢獻3000萬美元的淨營業收入和400萬美元的EBITDA，從而預計2025年的淨營業收入總額爲13000萬美元，調整後EBITDA爲2500萬美元。
The company recently announced its unaudited interim financial results on Thursday for the third quarter revealing CA$24.1 million ($17.2 million) in net revenue representing a 9% increase sequentially, but a 12% decrease year-over-year. However, gross margin before fair value adjustments reached 53% for the period, up from 44% in the prior year's period, reflecting improved operational efficiency.
該公司最近在週四公佈了未經審計的第三季度 interim financial results，顯示淨營業收入爲2410萬加元（1720萬美元），環比增長9%，同比下降12%。然而，在公允價值調整前的毛利率在該期間達到了53%，高於去年同期的44%，反映出運營效率的改善。
What's Next
接下來怎麼做
The offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange (TSXV).
該發行須獲得所有監管批准，包括tsxv的最終批准。
Now Read:
現在就閱讀吧:
- Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches
- Decibel大麻股報告第二季度淨營業收入同比下降22%，計劃通過新產品發佈獲益。
DBCCF Price Action
DBCCF價格動態
Decibel's shares traded 1.45% higher at $0.0476 per share after the market close on Friday afternoon.
Decibel的股票在週五下午市場收盤後上漲1.45%，每股交易價爲0.0476美元。
譯文內容由第三人軟體翻譯。
